Nuvalent, Inc. (NUVL.D)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $123.96
- As of
Kresmion compiles this page from NUVL.D's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Nuvalent, Inc. (NUVL.D): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-15.
See the full NUVL.D dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NUVL.D on one page. Preview it with sample data, then open it live with a free account.
Preview the NUVL.D dossierActive signals for NUVL.D
No recent signals on NUVL.D in the last 180 days.
FREE, NO ACCOUNT
Every signal on NUVL.D, as it fires
New filings, 13F moves and cross asset signals on NUVL.D land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NUVL.D (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 670703107 · 2026Q2 | $49.9M | 0.02% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 670703107 · 2026Q2 | $37.1M | 0.46% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 670703107 · 2026Q2 | $34.7M | 0.05% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 670703107 · 2026Q2 | $25.8M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 670703107 · 2026Q2 | $5.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 670703107 · 2026Q2 | $5.4M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 670703107 · 2026Q2 | $817K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NUVL.D
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NUVL.D against its peers
NUVL.D's return on equity of -34.1% ranks in the 38th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | NUVL.D | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 502M | n/a | 19 |
| Gross margin | n/a | 84.8% | n/a | 10 |
| Operating margin | n/a | -31.3% | n/a | 17 |
| Net margin | n/a | -30.1% | n/a | 17 |
| Return on equity | -34.1% | -21.2% | 38 | 19 |
| P / E | n/a | 31.2x | n/a | 6 |
Peers (23): PCVX, KRYS, APGE.D, IBRX, MDGL, CRNX.D, CYTK, KYMR, BMRN, CAI, PTGX, ARWR, TGTX, ABVX, SYRE, SMMT, ALKS, IONS, BBIO, PRAX, HALO, IOVA, NBIX. Left out: SBMFF (no annual filing), BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NUVL.D: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow NUVL.D on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to NUVL.D for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.